<DOC>
	<DOCNO>NCT03032536</DOCNO>
	<brief_summary>This open-label , randomize , multi-part study evaluate relative oral bioavailability tablet formulation AL-3778 ( formerly NVR 3-778 ) administer fasted fed condition ( Parts 1 2 ) drug-drug interaction AL-3778 entecavir tenofovir disoproxil fumarate ( Part 3 ) .</brief_summary>
	<brief_title>Study Relative Oral Bioavailability AL-3778 Tablets Drug Interaction With Entecavir Tenofovir Disoproxil Fumarate Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Main Inclusion Criteria All Subjects : 1 . Subject provide write consent . 2 . In investigator 's opinion , subject able understand comply protocol requirement , instruction , study restriction likely complete study plan . 3 . Subject good health deem investigator , base totality finding follow medical evaluation , include medical history , physical examination , laboratory test ECG . 4 . Male female , 1860 year age . 5 . Body mass index 1830 kg/m2 , inclusive . The minimum weight 50 kg . 6 . A female subject eligible participate study nonchildbearing potential ( defined female document tubal ligation , bilateral oophorectomy hysterectomy ) postmenopausal ( defined 12 month spontaneous amenorrhea follicle stimulate hormone level within laboratory 's reference range postmenopausal female ) . A postmenopausal female receive hormone replacement therapy willing discontinue hormone therapy 28 day study drug dose agrees remain hormone replacement therapy duration study may eligible study participation . 7 . If male , subject surgically sterile practicing require form birth control 6 month last dose study drug ( ) . Males must agree refrain sperm donation checkin 6 month last dose study drug ( ) . 8 . Subject nonsmoker use nicotine nicotinecontaining product least 6 month . 9 . Subjects participate Part 1 and/or Part 2 may participate subsequent Part ( ) upon satisfactory completion posttreatment visit , 7 day ( +2 day ) follow subject 's last dose , provide continue meet inclusion criterion none exclusion criterion . Main exclusion criterion : 1 . Subject mentally legally incapacitate , significant emotional problem time prestudy ( screen ) visit expect conduct study history clinically significant psychiatric disorder last 5 10 year . 2 . Subject history illness , opinion investigator , would confound objective result study pose additional risk subject participation study . 3 . Subject estimate creatinine clearance â‰¤80 mL/min base CockcroftGault equation ; An actual creatinine clearance , determine 24hour urine collection , may use place , conjunction , CockcroftGault equation ; subject actual estimate creatinine clearance within 10 % 80 mL/min may enrol study discretion investigator . 4 . Pregnant nursing ( lactate ) female , confirm positive human chorionic gonadotropin laboratory test female contemplate pregnancy . Men whose female partner pregnant contemplate pregnancy date screen 6 month last dose study drug . 5 . Clinically significant cardiovascular , respiratory , skeletal , renal , gastrointestinal , hematologic , hepatic , immunological , neurologic , endocrine , genitourinary abnormality disease medical illness determine investigator Sponsor 's Medical Monitor . 6 . Subject history malignancy except completely excise basal cell carcinoma squamous cell carcinoma skin . 7 . Subject lack poor peripheral venous access . 8 . Positive screen test hepatitis B , hepatitis C HIV serology . 9 . Any condition , opinion investigator , would compromise study 's objective wellbeing subject prevent subject meeting study requirement . 10 . Clinically significant abnormal ECG finding . Particularly , history family history prolong QT syndrome ( eg , torsade de pointes ) sudden cardiac death . 11 . ECG PR &gt; 200 m , QRS &gt; 120 m , QTcF &gt; 450 m , assess 12lead ECG screen visit . 12 . Subject major surgery , clinically significant blood loss elective blood donation significant volume ( ie , &gt; 500 mL ) within 60 day first dose study drug ; &gt; 1 unit plasma within 7 day first dose study drug . 13 . Abnormal heart rate , respiratory rate , temperature blood pressure value outside normal range ( evaluated semirecumbent recumbent position 5 minute rest ) . One repeat measurement additional 5 minute rest permit . 14 . Abnormal Alanine Aminotransferase , Aspartate Aminotransferase , gammaglutamyltransferase , albumin , total bilirubin , creatine kinase result 15 . Evidence active infection . 16 . Unwilling abstain alcohol least 48 hour prior start dose study completion visit . 17 . History regular alcohol intake &gt; 7 unit per week alcohol female &gt; 14 unit per week male ( one unit define 10 g alcohol ) within 3 month screen visit . 18 . The subject positive screening Day 1 drug abuse screen . 19 . The use concomitant medication , include prescription , counter medication , herbal medication ( St. John 's Wort [ Hypericum perforatum ] ) within 30 day prior first dose study medication exclude , unless approve Sponsor 's Medical Monitor . Occasional use paracetamol/ acetaminophen permit . 20 . Subject receive investigational drug ( include investigational vaccine ) use invasive investigational medical device within 90 day plan study drug . 21 . Subject history significant multiple and/or severe allergy , anaphylactic reaction significant intolerability prescription nonprescription drug food . 22 . Hypersensitivity active substance excipients AL3778 , entecavir tenofovir disoproxil fumarate . 23 . Subject know allergy heparin history heparininduced thrombocytopenia . 24 . Abnormal biochemistry hematology laboratory result obtain screen determine clinically significant Investigator . Screening ALT , AST , GGT , albumin , total bilirubin , creatine kinase must within normal range . 25 . Unwillingness inability comply study protocol reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>